<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0002842'>High blood pressure</z:mp> is reported in over two-thirds of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and its development coincides with the development of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Many pathophysiological mechanisms underlie this association </plain></SENT>
<SENT sid="2" pm="."><plain>Of these mechanisms, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in the nitric-<z:chebi fb="177" ids="25741,29356">oxide</z:chebi> pathway; the stimulatory effect of <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">hyperinsulinaemia</z:e> on sympathetic drive, smooth muscle growth, and <z:chebi fb="199" ids="26708">sodium</z:chebi>-fluid retention; and the excitatory effect of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> on the renin-angiotensin-<z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> system seem to be plausible </plain></SENT>
<SENT sid="3" pm="."><plain>In patients with <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> confers an enhanced risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>A blood pressure of lower than 140/85 mm Hg is a reasonable therapeutic goal in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> according to clinical trial evidence </plain></SENT>
<SENT sid="5" pm="."><plain>People with controlled <z:mp ids='MP_0002055'>diabetes</z:mp> have a similar cardiovascular risk to patients without <z:mp ids='MP_0002055'>diabetes</z:mp> but with <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>A renin-angiotensin system blocker combined with a <z:chebi fb="0" ids="50264">thiazide</z:chebi>-type <z:chebi fb="40" ids="35498">diuretic</z:chebi> might be the best initial <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> regimen for most people with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>In general, the positive effects of <z:chebi fb="0" ids="35674">antihypertensive drugs</z:chebi> on cardiovascular outcomes outweigh the negative effects of <z:chebi fb="0" ids="35674">antihypertensive drugs</z:chebi> on <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism </plain></SENT>
</text></document>